Orchid Pharma Ltd

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below are based on the company’s current position as of 21 January 2026, providing investors with the latest perspective on its performance and prospects.

Orchid Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from sideways movement to a mildly bearish trend. Despite some short-term bullish hints, the overall technical landscape suggests caution for investors as the stock grapples with persistent downward pressure.

Orchid Pharma Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish stance to a sideways trend. Despite some short-term bullish cues, the overall technical landscape remains bearish, reflecting ongoing challenges for the pharmaceutical company amid a significant price correction and underperformance relative to the broader market.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Orchid Pharma Ltd has exhibited a notable shift in price momentum as technical indicators reveal a complex interplay of bullish and bearish signals. Despite a 4.06% gain on 2 Jan 2026, the stock remains under pressure from longer-term bearish trends, reflecting a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

Orchid Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 30 December 2025, providing investors with the latest insights into its performance and valuation.

Orchid Pharma’s recent trading activity reveals a nuanced shift in price momentum, reflecting a complex interplay of technical indicators that suggest a transition from a mildly bullish stance to a more sideways trend. This development comes amid a backdrop of mixed signals from key momentum and trend-following tools, underscoring the challenges facing the Pharmaceuticals & Biotechnology sector in the current market environment.

Orchid Pharma has experienced a revision in its evaluation metrics reflecting ongoing operational challenges and market pressures. The pharmaceutical company’s recent assessment highlights shifts across key parameters including quality, valuation, financial trends, and technical outlook, underscoring the complexities faced by this small-cap player in the Pharmaceuticals & Biotechnology sector.

Orchid Pharma has exhibited a notable shift in its technical momentum, reflecting a nuanced interplay of bullish and bearish signals across key indicators. Recent market data reveals a mild bullish trend on weekly charts contrasting with more cautious monthly signals, underscoring a complex technical landscape for this Pharmaceuticals & Biotechnology stock.

Orchid Pharma, a player in the Pharmaceuticals & Biotechnology sector, has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average crosses above the 200-day moving average. This development often signals a potential bullish breakout, suggesting a shift in long-term momentum and a possible trend reversal for the stock.

Orchid Pharma has experienced a revision in its evaluation metrics reflecting a more cautious market assessment. This shift follows a series of financial and operational challenges that have influenced the company’s standing within the Pharmaceuticals & Biotechnology sector.

Orchid Pharma, a small-cap pharmaceutical company, has seen significant stock price fluctuations, currently priced at 857.95. The stock has experienced a 52-week high of 1,998.00 and a low of 603.80. Its performance over five years shows a substantial return compared to the Sensex, indicating potential resilience.

Orchid Pharma's stock has surged today, outperforming its sector and achieving consecutive gains over the past two days. Currently trading above key moving averages, the stock has shown a significant long-term increase despite recent declines. The broader market is also experiencing positive momentum, particularly among mid-cap stocks.

Orchid Pharma Ltd., a Chennai-based pharmaceutical company with operations spanning over 40 countries, has reported a consolidated net loss of ₹5.72 crores for Q2 FY26, marking a dramatic reversal from the ₹14.91 crores profit recorded in the previous quarter. The company's shares closed at ₹790.25 on November 12, down 3.87% from the previous session, as investors reacted to the concerning quarterly performance that saw the company slip into operating losses for the first time in recent quarters.